$2.15
-0.12 (-5.29%)
Open$2.25
Previous Close$2.27
Day High$2.25
Day Low$2.05
52W High$11.99
52W Low$2.15
Volume—
Avg Volume91.8K
Market Cap52.76M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+952.1% upside
Current
$2.15
$2.15
Target
$22.62
$22.62
$15.82
$22.62 avg
$24.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.82M | 10.52M | 11.40M |
| Net Income | 3.06M | 2.28M | 2.66M |
| Profit Margin | 25.9% | 21.7% | 23.3% |
| EBITDA | 4.32M | 3.67M | 4.36M |
| Free Cash Flow | 3.21M | 3.03M | 2.01M |
| Rev Growth | +9.7% | +22.7% | +8.4% |
| Debt/Equity | 0.16 | 0.13 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |